Abstracts tagged "juvenile myositis"

Abstract Number: 049 • Pediatric Rheumatology Symposium 2023
What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study
Kaveh Ardalan¹, Rebecca Fillipo¹, Christina ZIgler², Audrey Ward¹, Jeffrey Dvergsten³, Ann Reed¹, Alison Manning¹, Gary Maslow¹, Brian Feldman⁴, Ashley Danguecan⁵, Sarah Mossad⁵, Luana Flores Pereira⁵, Susan Shenoi⁶, Stacey Haynes⁷, Joanna Patten⁷ and Andrea Knight⁵, ¹Duke University School of Medicine, Durham, NC, ²Duke, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Seattle Children's Hospital, Seattle, WA, ⁷Seattle Childrens Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile myositis (JM) patients report high rates of emotional distress but qualitative studies suggest challenges accessing high quality mental health care. We present survey…
Abstract Number: 120 • Pediatric Rheumatology Symposium 2020
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Jessica Neely¹, Adam Huber ² and Susan Kim ³ for the CARRA investigators, ¹University of California, San Francisco, San Francisco, California, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³University of California, San Francisco, San Francisco
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
Abstract Number: 125 • Pediatric Rheumatology Symposium 2020
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
Kaveh Ardalan¹, Alison Manning ¹, Brian Feldman ², Gary Maslow ¹ and Andrea Knight ³, ¹Duke University Medical Center, Durham, ²The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada
Background/Purpose: Juvenile myositis (JM) negatively affects health-related quality of life due to chronic weakness, skin/muscle damage, multiorgan dysfunction, and side effects of immunosuppression. While JM’s…
Abstract Number: 433 • ACR/ARP Annual Meeting 2019
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Ruchi Patel ¹, Valeria Esparza ², Jin-Shei Lai ¹, Elizabeth Gray ¹, Rowland Chang ³, David Cella ³ and Kaveh Ardalan⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, ²University of Illinois-Chicago College of Medicine, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
Abstract Number: 775 • ACR/ARP Annual Meeting 2019
Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Lori Lowe ¹, Gabrielle Morgan ², Johann Gudjonsson ¹, Lauren Pachman ² and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago
Background/Purpose: Skin inflammation can herald systemic disease manifestations and disease chronicity in juvenile myositis (JM), yet we lack an understanding of the pathogenic mechanisms driving…
Abstract Number: 2241 • ACR/ARP Annual Meeting 2019
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Kaveh Ardalan¹, Oluwatosin Adeyemi ², Dawn Wahezi ³, Anne Caliendo ⁴, Megan L. Curran ⁵, Jessica Neely ⁶, Susan Kim ⁶, Colleen Correll ⁷, Emily Brunner ⁸ and Andrea Knight ⁹, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, ²Children's Hospital of Philadelphia, Philadelphia, ³Children’s Hospital at Montefiore, New York, ⁴Northwestern University Feinberg School of Medicine, Chicago, ⁵University of Colorado, Aurora, CO, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Minnesota, Minneapolis, ⁸Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…
Abstract Number: 481 • ACR/ARHP Annual Meeting 2018
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Emily Brunner¹, Laura Tasan², Kathryn S. Torok³, Bonny Rockette-Wagner⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch³, Diane Koontz⁶, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ⁶Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…
Abstract Number: 90 • Pediatric Rheumatology Symposium 2017
Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept
Sukesh Sukumaran¹ and Vini Vijayan², ¹ACH, UAMS, Little Rock, AR, ²Pediatrics, UAMS, Little Rock, AR
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic auto immune disease in children. The risk of infection is increased with immunomodulation. There are no studies…
Abstract Number: 1365 • ACR/ARHP Annual Meeting 2016
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, Nastaran Bayat², Michael Ward³, Adam Huber⁴, Lan Wu¹, Gulnara Mamyrova⁵, Ira Targoff⁶, William Warren-Hicks⁷, Frederick W. Miller², Lisa G. Rider⁸ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁶VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Social and Scientific Systems, Inc., Durham, NC, ⁸Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…
Abstract Number: 291 • ACR/ARHP Annual Meeting 2012
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 282 • ACR/ARHP Annual Meeting 2012
Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children
Gulnara Mamyrova¹, James D. Katz¹, Robert V. Jones², Peter A. Lachenbruch³, Mona Shah³, Olcay Y. Jones¹, Anupam Chahal¹, Seema Agrawal¹, Frederick W. Miller³, Lisa G. Rider³ and the Childhood Myositis Heterogeneity Group⁴, ¹Rheumatology, George Washington University, Washington, DC, ²Pathology, George Washington University, Washington, DC, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Niehs, NIH, Bethesda, MD
Background/Purpose: We examined demographic, clinical and laboratory features of juvenile polymyositis (JPM) and muscular dystrophy in children to improve classification of these two conditions. Methods:…